BMS reports sustained benefits of Camzyos in children with obstructive heart condition

The findings from the Phase 3 SCOUT-HCM trial strengthen the clinical evidence supporting Camzyos as the first approved cardiac myosin inhibitor for paediatric patients

Moderna Ebola vaccine candidate set to advance to Phase 2/3 trial in DR Congo

The recommendation was made after the World Health Organization's Technical Advisory Group on Candidate Vaccine Prioritization (TAG-CVP) reviewed the available evidence

Merck launches Phase 3 trial to test COPD drug’s po ltential to prevent disease exacerbations

The trial marks a significant step in Merck's efforts to expand the clinical evidence supporting OHTUVAYRE

Lilly’s experimental weight-loss drug beats Ozempic in head-to-head trial

The blood sugar results also favoured retatrutide

EU nod to Enhertu for early breast cancer cutting recurrence risk by 53%

The nod for Enhertu (trastuzumab deruxtecan) for patients with HER2-positive early breast cancer

BioNTech & Bristol Myers Squibb report 36.7% response rate for experimental lung cancer drug

The combination of pumitamig and chemotherapy drug docetaxel achieved a confirmed objective response rate of 36.7%

Lilly’s experimental lung cancer drug shows durable responses in early-stage trial data

The results strengthen the case for further testing olomorasib in a disease setting where treatment options remain limited

AstraZeneca’s Imfinzi combination cuts risk of death by 42% in muscle-invasive bladder cancer trial

The overall survival results were similarly encouraging

Roche’s experimental kidney drug cuts proteinuria by 43.1% in Phase III trial

The study also found that a greater proportion of patients with blood in their urine at baseline achieved resolution of haematuria by Week 37 with sefaxersen than with placebo

Prostate cancer drug cuts risk of metastasis or death by 58% in high-risk patients, Phase III trial finds

The findings point to a potential advance in treating patients with high-risk localised prostate cancer

Merck’s Pimicotinib shows sustained benefits in rare joint tumour

Tumour responses remained robust and durable, while the drug’s safety profile was consistent with previous analyses

Roche’s Divarasib cuts risk of death by 44% in advanced lung cancer trial

The findings mark a significant advance in the treatment of a lung cancer subtype for which more effective therapies remain urgently needed

Bristol Myers Squibb’s experimental cancer drug nearly doubles progression-free survival in Phase 3 lung cancer trial

The randomized, multicenter Phase 3 study is the first to evaluate a dual-targeting EGFRxHER3 bispecific antibody-drug conjugate in this patient population

Pfizer’s 25-valent pneumococcal vaccine shows strong Phase 2 results in infants

The Phase 2 study evaluated the vaccine’s safety, tolerability and immunogenicity in healthy infants, comparing it with PREVNAR 20

Bristol Myers Squibb’s cancer drug cuts risk of progression or death by 59% in Phase 3 breast cancer trial

The confirmed objective response rate was 40.5% among patients receiving iza-bren

Novartis’ Kisqali cuts risk of death by nearly 20% in early breast cancer, six-year trial data show

The findings demonstrate a sustained overall survival (OS) benefit in a broad population of patients with stage II and III early breast cancer

Novartis’ remibrutinib delivers 31–35% reduction in MS relapses

GSK’s cancer drug shows 61% response rate in global trial for aggressive lung cancer

Data from the Phase Ib dose-optimisation portion of the EMBOLD PanTumour-101 trial showed anti-tumour activity

Tezspire delivers significant improvements in eosinophilic esophagitis in Phase III trial

The trial met both co-primary endpoints at week 24, showing significant improvements in histologic remission and the frequency and severity of dysphagia

AbbVie’s dual-targeting Crohn’s Therapy shows higher remission rates in Phase 2a trial

The Phase 2a platform study enrolled 300 patients with moderately to severely active Crohn’s disease